Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 157Brain Neoplasms 98Glioma 69Gliosarcoma 43Astrocytoma 30Carcinoma, Non-Small-Cell Lung 19Recurrence 18Oligodendroglioma 18Central Nervous System Neoplasms 16Neoplasms 14Meningeal Carcinomatosis 10Ependymoma 10Meningioma 7Neurofibromatosis 2 6Neuroblastoma 6Melanoma 6Diffuse Intrinsic Pontine Glioma 6Neuroma, Acoustic 5Medulloblastoma 5Lung Neoplasms 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neurologic Manifestations 4Colorectal Neoplasms 4Breast Neoplasms 4Spinal Cord Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Bevacizumab × CNS × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡